MX2021001441A - Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso. - Google Patents
Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso.Info
- Publication number
- MX2021001441A MX2021001441A MX2021001441A MX2021001441A MX2021001441A MX 2021001441 A MX2021001441 A MX 2021001441A MX 2021001441 A MX2021001441 A MX 2021001441A MX 2021001441 A MX2021001441 A MX 2021001441A MX 2021001441 A MX2021001441 A MX 2021001441A
- Authority
- MX
- Mexico
- Prior art keywords
- solid state
- state form
- pyridine compounds
- methods
- pladienolide pyridine
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 150000003222 pyridines Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 210000001324 spliceosome Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente descripción proporciona una forma en estado sólido novedosa de compuesto de pladienolida piridina, composiciones que comprenden al menos una forma en estado sólido y métodos de preparación y uso de los mismos. La forma en estado sólido novedosa de compuestos de pladienolida piridina puede ser útil en el tratamiento de cáncer, tal como, por ejemplo, cánceres en los que los agentes que se dirigen a espliceosoma y las mutaciones de las mismas son conocidos siendo útiles.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257088P | 2015-11-18 | 2015-11-18 | |
| PCT/US2016/062525 WO2017087667A1 (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001441A true MX2021001441A (es) | 2022-05-19 |
Family
ID=57472076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001441A MX2021001441A (es) | 2015-11-18 | 2016-11-17 | Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso. |
| MX2018006155A MX2018006155A (es) | 2015-11-18 | 2016-11-17 | Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006155A MX2018006155A (es) | 2015-11-18 | 2016-11-17 | Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10745387B2 (es) |
| EP (1) | EP3377485B1 (es) |
| JP (2) | JP6312282B2 (es) |
| KR (1) | KR20180083376A (es) |
| CN (1) | CN108473479B (es) |
| AU (2) | AU2016357433B2 (es) |
| BR (1) | BR112018009995B1 (es) |
| CA (1) | CA3004623C (es) |
| ES (1) | ES2757174T3 (es) |
| IL (1) | IL259198B2 (es) |
| MD (1) | MD3377485T2 (es) |
| MX (2) | MX2021001441A (es) |
| RU (2) | RU2021102393A (es) |
| SG (2) | SG11201803519YA (es) |
| WO (1) | WO2017087667A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3774759A2 (en) * | 2018-04-09 | 2021-02-17 | Eisai R&D Management Co., Ltd. | Pladienolide compounds and their use |
| WO2019200100A1 (en) | 2018-04-12 | 2019-10-17 | Andrew Cook | Pladienolide derivatives as spliceosome targeting agents for treating cancer |
| KR20210016406A (ko) * | 2018-06-01 | 2021-02-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 스플라이싱 조정제를 사용하는 방법 |
| WO2021113755A2 (en) * | 2019-12-04 | 2021-06-10 | Pai Athma A | Anti-slc6a1 oligonucleotides and related methods |
| CA3199753A1 (en) | 2020-11-04 | 2022-05-12 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI312681B (en) | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| JP4459051B2 (ja) | 2002-07-31 | 2010-04-28 | メルシャン株式会社 | 新規生理活性物質 |
| CN1671856B (zh) | 2002-07-31 | 2010-05-12 | 卫材R&D管理株式会社 | 生理活性物质 |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| RU2330069C2 (ru) | 2002-11-29 | 2008-07-27 | Мершан Корпорейшн | Способ получения макролидного соединения и штаммы streptomyces sp., mortierella sp. и micromonosporaceae |
| EP1705247A4 (en) | 2003-11-27 | 2008-08-20 | Mercian Corp | DNA ACCOMPANYING HYDROXYLATION OF A MAKROLIDE COMPOUND |
| CA2552553C (en) | 2003-11-28 | 2015-01-06 | Kanagawa Academy Of Science And Technology | Method of detecting liver cancer, diagnostic for liver cancer and remedy for cancer |
| WO2006003706A1 (ja) | 2004-07-02 | 2006-01-12 | Plus One Techno & Co., Ltd. | 組み合わせ計量技術 |
| JP4599357B2 (ja) | 2004-07-20 | 2010-12-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドの生合成に関与するポリペプチドをコードするｄｎａ |
| TW200716744A (en) | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
| EP1935893A4 (en) | 2005-10-13 | 2009-07-22 | Eisai R&D Man Co Ltd | TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D |
| WO2008111464A1 (ja) * | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | スプライシング異常を指標とする抗ガン剤の作用検定方法 |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| JO3668B1 (ar) * | 2014-05-15 | 2020-08-27 | Eisai R&D Man Co Ltd | مركبات بلاديينوليد البيريدين وطرق استعمالها |
-
2016
- 2016-11-17 EP EP16805664.6A patent/EP3377485B1/en active Active
- 2016-11-17 IL IL259198A patent/IL259198B2/en unknown
- 2016-11-17 MX MX2021001441A patent/MX2021001441A/es unknown
- 2016-11-17 RU RU2021102393A patent/RU2021102393A/ru unknown
- 2016-11-17 JP JP2017528992A patent/JP6312282B2/ja active Active
- 2016-11-17 US US15/529,798 patent/US10745387B2/en active Active
- 2016-11-17 MX MX2018006155A patent/MX2018006155A/es unknown
- 2016-11-17 CN CN201680067749.5A patent/CN108473479B/zh active Active
- 2016-11-17 SG SG11201803519YA patent/SG11201803519YA/en unknown
- 2016-11-17 MD MDE20180923T patent/MD3377485T2/ro unknown
- 2016-11-17 WO PCT/US2016/062525 patent/WO2017087667A1/en active Application Filing
- 2016-11-17 KR KR1020187016598A patent/KR20180083376A/ko not_active Application Discontinuation
- 2016-11-17 BR BR112018009995-3A patent/BR112018009995B1/pt active IP Right Grant
- 2016-11-17 AU AU2016357433A patent/AU2016357433B2/en active Active
- 2016-11-17 SG SG10201913045PA patent/SG10201913045PA/en unknown
- 2016-11-17 ES ES16805664T patent/ES2757174T3/es active Active
- 2016-11-17 RU RU2018121610A patent/RU2743349C2/ru active
- 2016-11-17 CA CA3004623A patent/CA3004623C/en active Active
-
2018
- 2018-03-16 JP JP2018049098A patent/JP6353620B1/ja active Active
-
2020
- 2020-07-17 US US16/932,627 patent/US20200361915A1/en not_active Abandoned
-
2021
- 2021-02-15 AU AU2021200974A patent/AU2021200974B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264034A (en) | Crispr/cas9-based compositions and methods for treating cancer | |
| PH12016502249A1 (en) | Pladienolide pyridine compounds and methods of use | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| WO2018112365A3 (en) | Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii | |
| MX2021001441A (es) | Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso. | |
| TW201613648A (en) | Compounds and compositions for immunotherapy | |
| EP3377516A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| IL272844A (en) | Compounds, preparations and methods for the treatment or prevention of cancers resistant to HER-motor drugs | |
| MX2016010216A (es) | Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos. | |
| EP3348276A4 (en) | CANCER TREATMENT COMPOSITION COMPRISING ANTI-CD26 ANTIBODY AND ANOTHER CANCER AGENT | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| MY195739A (en) | Functionalised Benzopyran Compounds and use Thereof | |
| MX2022006304A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
| WO2019023315A3 (en) | RAC INHIBITORS | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| EP3298141A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
| EP3294301A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CANCER METASTAS AND METHODS THEREWITH | |
| EP3268028A4 (en) | Compositions and methods for treating cancer | |
| EP3322484A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
| PL3319638T3 (pl) | Kompozycja zawierająca cyneol do leczenia chorób nowotworowych i/lub raków |